Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...